Eton Pharmaceuticals (ETON) Income from Continuing Operations (2018 - 2026)
Eton Pharmaceuticals (ETON) posted Income from Continuing Operations of 1696000.0 for Q4 2025, up 188.01% sequentially from 1927000.0 in Q3 2025, and up 383.61% YoY from 350694.33 in Q4 2024.
Eton Pharmaceuticals (ETON) Income from Continuing Operations (2018 - 2026) Analysis & Trends
Eton Pharmaceuticals has reported Income from Continuing Operations for 8 years, with the latest figure at 1696000.0 in Q4 2025.
- Quarterly Income from Continuing Operations rose 383.61% year-over-year to 1696000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 4388000.0 (down 14.78% YoY) and the FY2025 annual result came in at 4388000.0, down 14.78% from the prior year.
- Income from Continuing Operations grew to 1696000.0 in Q4 2025 per ETON's latest filing, from 1927000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 5116000.0 in Q1 2021 and troughed at 6094000.0 in Q3 2021.
- A 5-year average of 891850.0 and a median of 1565000.0 in 2022 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2023 and 2025: Income from Continuing Operations soared 392.62% in 2023, then tumbled 407.34% in 2025.
- Over 5 years, Income from Continuing Operations stood at 1039000.0 in 2021, then jumped by 170.07% to 2806000.0 in 2022, then plunged by 166.43% to 1864000.0 in 2023, then soared by 67.92% to 598000.0 in 2024, then surged by 383.61% to 1696000.0 in 2025.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 1696000.0, 1927000.0, and 2585000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Eton Pharmaceuticals | 1.65 Bn | 1.62 Bn | 25.41 Mn | 11.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.58 Mn |
| Dec 31, 2025 | 1.70 Mn |
| Sep 30, 2025 | -1.93 Mn |
| Jun 30, 2025 | -2.59 Mn |
| Mar 31, 2025 | -1.57 Mn |
| Dec 31, 2024 | -598,000.00 |
| Sep 30, 2024 | 627,000.00 |
| Jun 30, 2024 | -3.04 Mn |
| Mar 31, 2024 | -811,000.00 |
| Dec 31, 2023 | -1.86 Mn |
| Sep 30, 2023 | -579,000.00 |
| Jun 30, 2023 | 4.56 Mn |
| Mar 31, 2023 | -2.66 Mn |
| Dec 31, 2022 | 2.81 Mn |
| Sep 30, 2022 | -3.05 Mn |
| Jun 30, 2022 | -1.56 Mn |
| Mar 31, 2022 | -5.33 Mn |
| Dec 31, 2021 | 1.04 Mn |
| Sep 30, 2021 | -6.09 Mn |
| Jun 30, 2021 | -2.02 Mn |